Trastuzumab

Generic Name
Trastuzumab
Brand Names
Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
Drug Type
Biotech
Chemical Formula
-
CAS Number
180288-69-1
Unique Ingredient Identifier
P188ANX8CK
Background

Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...

Indication

For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...

Associated Conditions
Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
Associated Therapies
-
Clinical Trials
Related News

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

First Posted Date
2021-10-18
Last Posted Date
2024-10-11
Lead Sponsor
Ascendis Pharma Oncology Division A/S
Target Recruit Count
473
Registration Number
NCT05081609
Locations
🇨🇳

Ascendis Pharma Investigational Site, Taipei, Taiwan

Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

First Posted Date
2021-10-13
Last Posted Date
2021-10-13
Lead Sponsor
Fudan University
Target Recruit Count
37
Registration Number
NCT05076695
Locations
🇨🇳

Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China

Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

First Posted Date
2021-09-30
Last Posted Date
2023-12-29
Lead Sponsor
Gruppo Oncologico del Nord-Ovest
Target Recruit Count
477
Registration Number
NCT05062889
Locations
🇮🇹

Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy

🇮🇹

Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, Lecce, Italy

🇮🇹

Ospedale San Donato di Arezzo, Arezzo, Italy

and more 25 locations

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

First Posted Date
2021-09-13
Last Posted Date
2024-10-17
Lead Sponsor
UNICANCER
Target Recruit Count
53
Registration Number
NCT05041842
Locations
🇫🇷

Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France

🇫🇷

Centre Francois Baclesse, Caen, France

🇫🇷

Centre Georges François Leclerc, Dijon, France

and more 12 locations

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

First Posted Date
2021-08-25
Last Posted Date
2024-01-16
Lead Sponsor
Baylor Breast Care Center
Target Recruit Count
185
Registration Number
NCT05020860
Locations
🇺🇸

Harris Health System - Smith Clinic, Houston, Texas, United States

🇺🇸

O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

First Posted Date
2021-08-12
Last Posted Date
2024-07-31
Lead Sponsor
ALX Oncology Inc.
Target Recruit Count
450
Registration Number
NCT05002127
Locations
🇺🇸

The Oncology Institute of Hope & Innovation, Anaheim, California, United States

🇺🇸

University of California Los Angeles, Los Angeles, California, United States

🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 80 locations

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

First Posted Date
2021-08-06
Last Posted Date
2021-08-06
Lead Sponsor
AC Camargo Cancer Center
Target Recruit Count
80
Registration Number
NCT04993014
Locations
🇧🇷

A.C. Camargo Cancer Center, São Paulo, Brazil

Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

Phase 3
Not yet recruiting
Conditions
Breast Cancer
Interventions
Drug: Pyrotinib
Drug: Trastuzumab
First Posted Date
2021-07-22
Last Posted Date
2021-07-22
Lead Sponsor
Shengjing Hospital
Target Recruit Count
450
Registration Number
NCT04973319
Locations
🇨🇳

Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, China

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

First Posted Date
2021-07-15
Last Posted Date
2021-07-15
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
240
Registration Number
NCT04962425
Locations
🇨🇳

Peking University Third Hospital, Peking, Beijing, China

Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

First Posted Date
2021-07-14
Last Posted Date
2021-07-14
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
30
Registration Number
NCT04961307
Locations
🇨🇳

Peking University Third Hospital, Peking, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy